CAPLIN POINT’S CRO AMARIS CLINICAL COMPLETES USFDA AUDIT WITH NIL OBSERVATIONS
Chennai, Sep 24, 2021: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Amaris Clinicals (Amaris), the Clinical Research Organization (CRO) division of Caplin Point Laboratories Limited, located at Chennai, has completed a virtual audit from United States Food and Drug Administration (USFDA) with NIL observations. Chairman C. C. Paarthipan commented “It is an excellent…